BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37029081)

  • 1. Clinical characteristics and long-term outcomes for parapharyngeal metastases of well-differentiated thyroid cancer during
    Deng XZ; Shi YF; Shen CT; Song HJ; Wang J; Fan YB; Luo QY; Qiu ZL
    Clin Endocrinol (Oxf); 2023 Jul; 99(1):92-102. PubMed ID: 37029081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up.
    Qiu ZL; Shen CT; Sun ZK; Song HJ; Xi C; Zhang GQ; Wang Y; Luo QY
    Front Endocrinol (Lausanne); 2020; 11():588024. PubMed ID: 33716950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases.
    Mihailovic J; Stefanovic L; Malesevic M; Markoski B
    Thyroid; 2009 Mar; 19(3):227-32. PubMed ID: 19265493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of radioiodine avidity and serum thyroglobulin in differentiated thyroid carcinoma with distant metastasis.
    Kim HJ; Lee JI; Kim NK; Min YK; Kim SW; Chung JH
    World J Surg; 2013 Dec; 37(12):2845-52. PubMed ID: 24085223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy.
    Qiu ZL; Shen CT; Luo QY
    Thyroid; 2015 Feb; 25(2):229-37. PubMed ID: 25331724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland.
    Nixon IJ; Whitcher MM; Palmer FL; Tuttle RM; Shaha AR; Shah JP; Patel SG; Ganly I
    Thyroid; 2012 Sep; 22(9):884-9. PubMed ID: 22827579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung Metastases From Papillary Thyroid Cancer With Persistently Negative Thyroglobulin and Elevated Thyroglobulin Antibody Levels During Radioactive Iodine Treatment and Follow-Up: Long-Term Outcomes and Prognostic Indicators.
    Qiu ZL; Shen CT; Sun ZK; Song HJ; Zhang GQ; Luo QY
    Front Endocrinol (Lausanne); 2019; 10():903. PubMed ID: 31998236
    [No Abstract]   [Full Text] [Related]  

  • 8. Management and outcome of recurrent well-differentiated thyroid carcinoma.
    Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
    van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
    Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.
    Lang BH; Wong KP; Cheung CY; Wan KY; Lo CY
    Ann Surg Oncol; 2013 Apr; 20(4):1329-35. PubMed ID: 23104708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES.
    Slook O; Levy S; Slutzky-Shraga I; Tsvetov G; Robenshtok E; Shimon I; Benbassat C; Hirsch D
    Endocr Pract; 2019 May; 25(5):427-437. PubMed ID: 30657361
    [No Abstract]   [Full Text] [Related]  

  • 12. Improved Survival After Multimodal Approach with
    Wu D; Gomes Lima CJ; Moreau SL; Kulkarni K; Zeymo A; Burman KD; Wartofsky L; Van Nostrand D
    Thyroid; 2019 Jul; 29(7):971-978. PubMed ID: 31017051
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up.
    Sohn SY; Kim HI; Kim YN; Kim TH; Kim SW; Chung JH
    Clin Endocrinol (Oxf); 2018 Feb; 88(2):318-326. PubMed ID: 28972676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors.
    Lee J; Soh EY
    Ann Surg; 2010 Jan; 251(1):114-9. PubMed ID: 19779325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
    Song E; Ahn J; Jeon MJ; Lee SM; Lee JH; Kim TY; Baek JH; Kim WB; Shong YK; Kim WG
    Thyroid; 2020 Mar; 30(3):418-424. PubMed ID: 31880976
    [No Abstract]   [Full Text] [Related]  

  • 16. Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma.
    Sabet A; Binse I; Dogan S; Koch A; Rosenbaum-Krumme SJ; Biersack HJ; Biermann K; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):190-195. PubMed ID: 27530124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.
    Zhang XY; Sun JW; Qiu ZL; Wang Y; Chen XY; Zhao JH; Luo QY
    Endocrine; 2019 Nov; 66(2):254-265. PubMed ID: 31317522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
    Mihailovic J; Nikoletic K; Srbovan D
    J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
    Mazzaferri EL; Jhiang SM
    Am J Med; 1994 Nov; 97(5):418-28. PubMed ID: 7977430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
    Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
    Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.